Literature DB >> 11544451

Dexamethasone inhibits the binding of nuclear factors to the IL-5 promoter in human CD4 T cells.

A Quan1, M N McCall, W A Sewell.   

Abstract

BACKGROUND: IL-5 is produced by the T(H)2 subset of CD4(+) T lymphocytes and is necessary for the eosinophilia typical of allergic conditions. Glucocorticoids such as dexamethasone are highly effective inhibitors of eosinophilic inflammation, and one of their effects is inhibition of IL-5 gene expression.
OBJECTIVE: We wished to examine the effect of dexamethasone on the binding of nuclear factors from primary human CD4(+) T lymphocytes to the RE-I and RE-II positively acting regulatory elements of the IL-5 promoter.
METHODS: CD4(+) T cells, purified from PBMCs by magnetic bead separation, were activated with anti-CD3 antibody and phorbol myristate acetate. Nuclear extracts were tested in electrophoretic mobility shift assays with probes based on RE-I and RE-II.
RESULTS: In extracts from activated cells, the RE-II region of the promoter formed a complex that was shown by supershift assay to contain NFATc. This complex was abolished by treatment of the cells with dexamethasone before activation and was weak or absent in unactivated cells. By contrast, binding to the RE-I region and to the GATA-3 site within RE-I was observed in resting cells and was not affected by activation or treatment with dexamethasone.
CONCLUSION: Dexamethasone inhibits the inducible binding of factors to the RE-II region but does not affect the constitutive binding to the RE-I region. Characterization of such molecular effects of glucocorticoids could enable the development of specific inhibitors of IL-5 expression that lack the side effects of glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544451     DOI: 10.1067/mai.2001.118512

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome.

Authors:  Grant J Logan; Allison P Dane; Claus V Hallwirth; Christine M Smyth; Emilie E Wilkie; Anais K Amaya; Erhua Zhu; Neeta Khandekar; Samantha L Ginn; Sophia H Y Liao; Sharon C Cunningham; Natsuki Sasaki; Martí Cabanes-Creus; Patrick P L Tam; David W Russell; Leszek Lisowski; Ian E Alexander
Journal:  Nat Genet       Date:  2017-06-19       Impact factor: 38.330

2.  Transcriptional regulation of the IL-5 gene in peripheral T cells of asthmatic patients.

Authors:  K Ogawa; O Kaminuma; H Okudaira; H Kikkawa; K Ikezawa; N Sakurai; A Mori
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

3.  Compound A, a dissociated glucocorticoid receptor modulator, inhibits T-bet (Th1) and induces GATA-3 (Th2) activity in immune cells.

Authors:  Ana C Liberman; Maria Antunica-Noguerol; Viviane Ferraz-de-Paula; Joao Palermo-Neto; Carla N Castro; Jimena Druker; Florian Holsboer; Marcelo J Perone; Sarah Gerlo; Karolien De Bosscher; Guy Haegeman; Eduardo Arzt
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

4.  Dexamethasone inhibits IL-9 production by human T cells.

Authors:  Lauren E Holz; Kristoffer P Jakobsen; Jacques Van Snick; Francoise Cormont; William A Sewell
Journal:  J Inflamm (Lond)       Date:  2005-04-20       Impact factor: 4.981

5.  GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells.

Authors:  Pierre-Yves Mantel; Harmjan Kuipers; Onur Boyman; Claudio Rhyner; Nadia Ouaked; Beate Rückert; Christian Karagiannidis; Bart N Lambrecht; Rudolf W Hendriks; Reto Crameri; Cezmi A Akdis; Kurt Blaser; Carsten B Schmidt-Weber
Journal:  PLoS Biol       Date:  2007-12       Impact factor: 8.029

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.